Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock

Rhea-AI Filing Summary

Lewis H. Titterton Jr., a director of Anixa Biosciences Inc (ANIX), reported an open-market purchase of 2,797 shares of common stock on July 15, 2026 at $3.28 per share. After this transaction, he directly holds 974,967 shares of Anixa common stock.

Insider Trade Summary

Net Buyer: 2,797 shares ($9,174)

Net Buy 1 txn

Insider Titterton Lewis H jr

Role Director

Bought 2,797 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,797	$3.28	$9K

Holdings After Transaction: Common Stock — 974,967 shares (Direct)

Footnotes (1)

Key Figures

Shares purchased: 2,797 shares Purchase price: $3.28 per share Shares owned after: 974,967 shares

3 metrics

Shares purchased 2,797 shares Open-market purchase of Anixa Biosciences common stock on July 15, 2026

Purchase price $3.28 per share Price paid per share in the reported open-market transaction

Shares owned after 974,967 shares Director’s direct holdings of Anixa Biosciences common stock after the purchase

Key Terms

open-market purchase, direct ownership, Common Stock

3 terms

open-market purchase financial

"Reported as an open-market purchase of common stock."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

direct ownership financial

"Following the transaction, shares are held under direct ownership."

Common Stock financial

"Transaction involved Anixa Biosciences Inc Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 09:00 AM Accepted by SEC EDGAR 07/16/2026 - 09:00 AM Learn about SEC filing dates

FAQ

What insider transaction did Anixa Biosciences (ANIX) report for Lewis H. Titterton Jr.?

Anixa Biosciences reported that director Lewis H. Titterton Jr. bought 2,797 shares of common stock. The shares were acquired in an open-market purchase at $3.28 per share, increasing his direct ownership position in the company.

When did the recent Anixa Biosciences (ANIX) insider purchase occur and at what price?

The insider purchase occurred on July 15, 2026 at a price of $3.28 per share. Director Lewis H. Titterton Jr. executed an open-market transaction for Anixa Biosciences common stock, as disclosed in the reported Form 4 insider filing.

How many Anixa Biosciences (ANIX) shares does Lewis H. Titterton Jr. now own?

Following the reported transaction, Lewis H. Titterton Jr. directly owns 974,967 shares of Anixa Biosciences common stock. This figure reflects his updated direct holdings after purchasing 2,797 shares in the open market on July 15, 2026.

Was the Anixa Biosciences (ANIX) insider transaction reported as direct or indirect ownership?

The transaction was reported as direct ownership of Anixa Biosciences common stock. The Form 4 indicates ownership type "D," meaning the purchased 2,797 shares and the resulting 974,967-share position are held directly by Lewis H. Titterton Jr.

Does the Anixa Biosciences (ANIX) Form 4 include any derivative security transactions?

The Form 4 for Anixa Biosciences lists only a common stock transaction and shows no derivative security entries. There are no reported option exercises, warrant conversions, or other derivative positions associated with this particular insider filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Titterton Lewis H jr

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		P		2,797	A	$3.28	974,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lewis H. Titterton, Jr.	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)